State updates - 04/10/2026

California

Two bills are moving through the California legislature this week, and both are worth paying attention to.

AB 2141 cleared the Business & Professions Committee and would create a more streamlined process for the California Board of Pharmacy to resolve certain enforcement cases while maintaining full oversight – a practical fix that addresses a real gap in the current system. Chairman Marc Berman has also signed on as a principal co-author, a sign of growing support for the measure. APC has been advocating for exactly this kind of interim step, and we'll be watching its progress closely.

AB 1990, introduced by Representative Gibson, is a different story. Similar to legislation introduced in other states this year, it would significantly restrict compounding of GLP-1 drugs. The bill has hearings scheduled in the Business & Professions Committee on April 14 and the Privacy and Consumer Protection Committee on April 21. APC's Tenille Davis will be in Sacramento to testify in opposition at the first hearing.

Colorado

SB 26-066 has been laid over again. At this point we're not surprised, and neither should you be. We'll keep you posted if anything actually changes.

On a separate front, APC Board Chair Philip Smyth testified this week in support of Colorado HB 1262, which aims to bring state law into alignment with the federal framework governing how 503A pharmacies and 503B outsourcing facilities work together. There's been persistent confusion at the state level about whether distribution from 503B facilities to 503A pharmacies constitutes wholesaling – despite FDA guidance making clear that it does not. HB 1262 clarifies that distinction without expanding compounding authority. An amendment was adopted during the hearing and the bill has advanced to the Committee of the Whole. One notable moment: a Lilly representative testifying against the bill suggested that lawmakers stay tuned to a certain podcast for guidance on where FDA policy is headed. We'll let you read between the lines on that one.

Georgia

The Georgia legislature officially adjourned its 2026 session on April 2 – sine die – and HB 1361 died with it. The bill would have imposed significant new restrictions on pharmacy compounding, and like so many of its cousins introduced around the country this year, it didn't make it across the finish line. We'll be watching for what gets reintroduced when the next session begins.